There is strong evidence to support RAAS antagonists, such as ACE inhibitors (ACEI) and angiotensin receptor blockers (ARB), as first-choice drugs for both adults and children with CKD [25, 32, 38]. This evidence concerns the gene ACE and chronic kidney disease.